Skip to content

IRIS-Onyx Cohort in the IRIS-DES Registry

Evaluation of Effectiveness and Safety of Resolute Onyx™ and Onyx Frontier™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02593994
Acronym
IRIS-Onyx
Enrollment
4500
Registered
2015-11-02
Start date
2015-10-01
Completion date
2031-12-31
Last updated
2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Occlusive Diseases, Cardiovascular Diseases, Coronary Artery Disease, Percutaneous Transluminal Angioplasty

Keywords

Onyx, drug eluting stent, Routine Clinical Practice, Angioplasty, Transluminal, Percutaneous Coronary, Coronary Artery Disease

Brief summary

The purpose of this study is to evaluate the relative effectiveness and safety of Onyx stent compared to other (drug eluting stents) DES.

Interventions

DEVICEOnyx Drug Eluting Stent group

Sponsors

Seung-Jung Park
Lead SponsorOTHER
CardioVascular Research Foundation, Korea
CollaboratorOTHER
Medtronic Korea Co., Ltd.
CollaboratorUNKNOWN

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 19 and more * Intervention with Onyx Drug Eluting Stent * Agreed with written informed consent form

Exclusion criteria

* Intervention with Onyx drug eluting coronary stent and other drug eluting stent at the same time * Life expectancy of 1year and under * Cardiac shock

Design outcomes

Primary

MeasureTime frameDescription
Stent thrombosis1 yearAs per Academic Research Consortium (ARC) standard, definite or probable stent thrombosis

Secondary

MeasureTime frameDescription
All death5 year
Cardiac death5 year
Myocardial infarction5 year
Composite event of death or myocardial infarction5 year
Composite event of cardiac death or myocardial infarction5 year
Composite event rate5 yeardeath, myocardial infarction, target vessel revascularization
Target Vessel revascularization5 year
Target Lesion revascularization5 year
Stent thrombosis5 year
Stroke5 year
Procedural success3 daydefined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 25, 2026